Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation

Virus-specific T-cells from third party or transplant donors for treatment of EBV lymphoproliferative diseases arising post hematopoietic cell or solid organ transplantation

Blog Article

EBV+ lymphomas constitute Chalkboards a significant cause of morbidity and mortality in recipients of allogeneic hematopoietic cell (HCT) and solid organ transplants (SOT).Phase I and II trials have shown that in HCT recipients, adoptive transfer of EBV-specific T-cells from the HCT donor can safely induce durable remissions of EBV+ lymphomas including 70->90% of patients who have failed to respond to treatment with Rituximab.More recently, EBV-specific T-cells generated from allogeneic 3rd party donors have also been shown to induce durable remission of EBV+ lymphomas in Rituximab refractory HCT and SOT recipients.In this review, we compare results of phase I and II trials of 3rd party and donor derived EBV-specific T-cells.

We GUTSHOT GARLIC DILL PICKLE focus on the attributes and limitations of each product in terms of access, safety, responses achieved and durability.The limited data available regarding donor and host factors contributing to T cell persistence is also described.We examine factors contributing to treatment failures and approaches to prevent or salvage relapse.Lastly, we summarize strategies to further improve results for virus-specific immunotherapies for post-transplant EBV lymphomas.